WO2022106984A3 - Small molecule inhibitors of sars-cov2 main protease - Google Patents

Small molecule inhibitors of sars-cov2 main protease Download PDF

Info

Publication number
WO2022106984A3
WO2022106984A3 PCT/IB2021/060572 IB2021060572W WO2022106984A3 WO 2022106984 A3 WO2022106984 A3 WO 2022106984A3 IB 2021060572 W IB2021060572 W IB 2021060572W WO 2022106984 A3 WO2022106984 A3 WO 2022106984A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov2
sars
small molecule
molecule inhibitors
main protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/060572
Other languages
French (fr)
Other versions
WO2022106984A2 (en
Inventor
Oleksandr Buzko
J. Gardner NELSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
NantCell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NantCell Inc filed Critical NantCell Inc
Publication of WO2022106984A2 publication Critical patent/WO2022106984A2/en
Publication of WO2022106984A3 publication Critical patent/WO2022106984A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are therapeutic compositions for the prevention, amelioration and/or treatment of infectious disease, including, but not limited to, SARS-COV2.
PCT/IB2021/060572 2020-11-18 2021-11-15 Small molecule inhibitors of sars-cov2 main protease Ceased WO2022106984A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063115461P 2020-11-18 2020-11-18
US63/115,461 2020-11-18

Publications (2)

Publication Number Publication Date
WO2022106984A2 WO2022106984A2 (en) 2022-05-27
WO2022106984A3 true WO2022106984A3 (en) 2022-07-07

Family

ID=78827896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/060572 Ceased WO2022106984A2 (en) 2020-11-18 2021-11-15 Small molecule inhibitors of sars-cov2 main protease

Country Status (1)

Country Link
WO (1) WO2022106984A2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D.L. MCKEE, ET AL.: "Candidate drugs against SARS-CoV-2 and COVID-19", PHARMACOLOGICAL RESEARCH, vol. 157, 104859, 29 April 2020 (2020-04-29), Elsevier, Oxford, GB, XP086154221, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2020.104859 *
LU ZHENG, ET AL.: "Potential treatment methods targeting 2019-nCoV infection", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 205, 112687, 28 July 2020 (2020-07-28), Elsevier Masson, Paris, FR, XP086277986, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112687 *

Also Published As

Publication number Publication date
WO2022106984A2 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2022015812A (en) Inhibitors of cysteine proteases and methods of use thereof.
MY209609A (en) Immunomodulators, compositions and methods thereof
MX2023012981A (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use.
EP4520328A3 (en) Heterocyclic compounds as immunomodulators
WO2020160193A3 (en) Compounds and uses thereof
EP4566675A3 (en) Heterocyclic compounds as immunomodulators
GEP20257731B (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
MX2021001186A (en) Purinones as ubiquitin-specific protease 1 inhibitors.
BR112022000505A8 (en) N-substituted 3,4-(5-fused-ring)-5-phenyl-pyrrolidin-2-one compounds as isoqc and/or qc enzyme inhibitors
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023009685A (en) Tyk2 inhibitors and uses thereof.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
JOP20230250A1 (en) Formulations and methods for inhibiting the ketohexokinase (KHK) enzyme
EP4252755A3 (en) Therapeutic compounds
PH12022550130A1 (en) Enzyme inhibitors
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2023001296A (en) Compositions and methods for treating diseases and disorders.
MX2022014007A (en) Compounds as bcl-2 inhibitors.
PH12022552447A1 (en) Nlrp3 modulators
MX2023005913A (en) Benzenesulfonamide derivatives and uses thereof.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2024099364A3 (en) Fused multicyclic compounds and their use as parp1 inhibitors
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
MX2024014262A (en) Inhibitors of parg

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21823364

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21823364

Country of ref document: EP

Kind code of ref document: A2